ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,121 to 4,140 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding619 of 770

654 of 814

0.0 points

-3.9 to 4.0

1,584NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding329 of 770

341 of 814

0.8 points

-4.0 to 5.7

1,584NCT00391872

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Pagibaximab vs Placebo: The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.85 of 792

79 of 787

0.7 points

-2.3 to 3.7

1,579NCT00646399

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): All Cause Mortality at 6 Hours56 of 784

68 of 795

-1.4 points

-4.1 to 1.3

1,579NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Death From Bleeding at 6 Hours32 of 784

35 of 795

-0.3 points

-2.4 to 1.7

1,579NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period61 of 792

69 of 786

-1.1 points

-3.8 to 1.7

1,578NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): All Cause Mortality at 24 Hours88 of 783

97 of 794

-1.0 points

-4.2 to 2.2

1,577NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Death From Bleeding at 24 Hours43 of 783

39 of 794

0.6 points

-1.6 to 2.8

1,577NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Abatacept (LT) vs Abatacept (ST): serious adverse events61 of 530

110 of 1,046

1.0 points

-2.2 to 4.4

1,576NCT00124982

Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy

Dabigatran 220mg vs Enoxaparin: Number of Participants With Total Deep Vein Thrombosis During Treatment Period60 of 791

67 of 784

-1.0 points

-3.7 to 1.7

1,575NCT00657150

Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty

Regional Anesthesia vs General Anesthesia: Inpatient Mortality5 of 782

13 of 790

-1.0 points

-2.2 to 0.1

1,572NCT02507505

Regional Versus General Anesthesia for Promoting Independence After Hip Fracture

Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)267 of 785

206 of 787

7.8 points

3.3 to 12.3

1,572NCT03675737

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Pembrolizumab + Chemotherapy (FP or CAPOX Regimen) vs Placebo + Chemotherapy (FP or CAPOX Regimen): Number of Participants Who Experienced an Adverse Event (AE)776 of 785

771 of 787

0.9 points

-0.4 to 2.2

1,572NCT03675737

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With a Deep Incisional or Organ/Space Infection46 of 787

51 of 784

-0.7 points

-3.1 to 1.7

1,571NCT03385304

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

10% Povidone-iodine (1% Free Iodine) in Purified Water vs 4% Chlorhexidine Gluconate (CHG) in Purified Water: Number of Participants With a Superficial Incisional Surgical Site Infection (SSI)13 of 787

7 of 784

0.8 points

-0.4 to 2.0

1,571NCT03385304

Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures

Roflumilast vs Placebo: serious adverse events157 of 778

183 of 790

-3.0 points

-7.1 to 1.1

1,568NCT00297115

Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)

Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): Number of Participants With Treatment-emergent Adverse Events (TEAEs)346 of 458

1,052 of 1,110

-19.2 points

-23.5 to -15.2

1,568NCT02782104

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): deaths from any cause1 of 458

8 of 1,110

-0.5 points

-1.2 to 0.6

1,568NCT02782104

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Esketamine Nasal Spray (IND Phase) vs Esketamine Nasal Spray (OP/MA Phase): serious adverse events5 of 458

212 of 1,110

-18.0 points

-20.5 to -15.4

1,568NCT02782104

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

Pravastatin Group vs Control Group: serious adverse events188 of 780

164 of 785

3.2 points

-0.9 to 7.3

1,565NCT00221104

Japan Statin Treatment Against Recurrent Stroke (J-STARS)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=207"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=207

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00391872-2036f827",
        "title": "TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Bleeding",
        "summary": "619 of 770 against 654 of 814; risk difference 0.0 points, 95% interval -3.9 to 4.0; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00391872-2036f827",
        "nct_id": "NCT00391872",
        "kind": "outcome",
        "participants": 1584,
        "risk_difference": {
          "value": 0.00045630045630040694,
          "lower": -0.03878350983653005,
          "upper": 0.03952284529313485
        },
        "group_1": "619 of 770",
        "group_2": "654 of 814",
        "difference": "0.0 points",
        "interval": "-3.9 to 4.0",
        "trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
      },
      {
        "id": "NCT00391872-f0fb560f",
        "title": "TICAGRELOR vs CLOPIDOGREL: Participants With Coronary Artery Bypass Graft (CABG) Major Fatal/Life-threatening Bleeding",
        "summary": "329 of 770 against 341 of 814; risk difference 0.8 points, 95% interval -4.0 to 5.7; NCT00391872, A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome",
        "record": "/library/comparisons/NCT00391872-f0fb560f",
        "nct_id": "NCT00391872",
        "kind": "outcome",
        "participants": 1584,
        "risk_difference": {
          "value": 0.008353808353808334,
          "lower": -0.04021889635098807,
          "upper": 0.05691437205124145
        },
        "group_1": "329 of 770",
        "group_2": "341 of 814",
        "difference": "0.8 points",
        "interval": "-4.0 to 5.7",
        "trial_title": "A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=208",
  "request_id": "PExbif8P5Wkx9CrJ"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?